
Daria Lucia Trabattoni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2172095/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ls there a risk of virus contamination through pneumoperitoneum during laparoscopic surgery in patients with COVID-19? A cadaveric study. Minerva Urology and Nephrology, 2022, 74, .	1.3	0
2	Pregnant Women Develop a Specific Immunological Long-Lived Memory Against SARS-COV-2. Frontiers in Immunology, 2022, 13, 827889.	2.2	5
3	Leishmania tarentolae as an Antigen Delivery Platform: Dendritic Cell Maturation after Infection with a Clone Engineered to Express the SARS-CoV-2 Spike Protein. Vaccines, 2022, 10, 803.	2.1	3
4	ERAPs Reduce In Vitro HIV Infection by Activating Innate Immune Response. Journal of Immunology, 2021, 206, 1609-1617.	0.4	5
5	UV-C irradiation is highly effective in inactivating SARS-CoV-2 replication. Scientific Reports, 2021, 11, 6260.	1.6	207
6	Early-Transmitted Variants and Their Evolution in a HIV-1 Positive Couple: NGS and Phylogenetic Analyses. Viruses, 2021, 13, 513.	1.5	1
7	Emergency Lung Transplantation after COVID-19: Immunopathological Insights on Two Affected Patients. Cells, 2021, 10, 611.	1.8	11
8	Unlikely SARS-CoV-2 Transmission During Vaginal Delivery. Reproductive Sciences, 2021, 28, 2939-2941.	1.1	15
9	The Modulation of Cholesterol Metabolism Is Involved in the Antiviral Effect of Nitazoxanide. Infectious Disease Reports, 2021, 13, 636-644.	1.5	1
10	Solar UV-B/A radiation is highly effective in inactivating SARS-CoV-2. Scientific Reports, 2021, 11, 14805.	1.6	27
11	Severity of COVID-19 Patients Predicted by Serum Sphingolipids Signature. International Journal of Molecular Sciences, 2021, 22, 10198.	1.8	45
12	Immunological Characterization of HIV and SARS-CoV-2 Coinfected Young Individuals. Cells, 2021, 10, 3187.	1.8	8
13	Anti-Inflammatory Effects of Immunostimulation in Patients with COVID-19 Pneumonia. Journal of Clinical Medicine, 2021, 10, 5765.	1.0	3
14	New Insights in the Fight against HIV. Cells, 2021, 10, 3549.	1.8	0
15	IL-21 is associated with natural resistance to HIV-1 infection in a Colombian HIV exposed seronegative cohort. Microbes and Infection, 2020, 22, 371-374.	1.0	5
16	Forcing Seasonality of Influenza-like Epidemics with Daily Solar Resonance. IScience, 2020, 23, 101605.	1.9	9
17	Analysis of SARS-CoV-2 vertical transmission during pregnancy. Nature Communications, 2020, 11, 5128.	5.8	284
18	Sterol metabolism modulates susceptibility to HIV-1 Infection. Aids, 2020, 34, 1593-1602.	1.0	12

2

#	Article	IF	CITATIONS
19	Endoplasmic Reticulum Associated Aminopeptidase 2 (ERAP2) Is Released in the Secretome of Activated MDMs and Reduces in vitro HIV-1 Infection. Frontiers in Immunology, 2019, 10, 1648.	2.2	24
20	Higher Levels of Peripheral Th17 T CD4+ Cells Are Associated With Immunological Non Response in HIV-Infected Patients Under Effective ART. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, e45-e47.	0.9	2
21	Interleukin 21 (IL-21)/microRNA-29 (miR-29) axis is associated with natural resistance to HIV-1 infection. Aids, 2018, 32, 2453-2461.	1.0	31
22	The NLRP3 Inflammasome Is Upregulated in HIV-Infected Antiretroviral Therapy-Treated Individuals with Defective Immune Recovery. Frontiers in Immunology, 2018, 9, 214.	2.2	71
23	Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen. Journal of Antimicrobial Chemotherapy, 2018, 73, 2162-2170.	1.3	6
24	Humoral and cell-mediated immune responses after a booster dose of HBV vaccine in HIV-infected children, adolescents and young adults. PLoS ONE, 2018, 13, e0192638.	1.1	8
25	Immune correlates of protection against HIV infection and how to elicit them. Mucosal Immunology, 2017, 10, 827-828.	2.7	4
26	Immunomodulatory effects of pidotimod in adults with community-acquired pneumonia undergoing standard antibiotic therapy. Pulmonary Pharmacology and Therapeutics, 2017, 44, 24-29.	1.1	25
27	A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infection. Microbes and Infection, 2017, 19, 69-74.	1.0	9
28	The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses. International Journal of Molecular Sciences, 2017, 18, 2127.	1.8	10
29	High Expression of Antiviral and Vitamin D Pathway Genes Are a Natural Characteristic of a Small Cohort of HIV-1-Exposed Seronegative Individuals. Frontiers in Immunology, 2017, 8, 136.	2.2	15
30	Evaluation of Th9 lymphocytes in peripheral blood of rheumatoid arthritis patients and correlation with anti-tumor necrosis factor therapy: results from an in vitro pivotal study. Reumatismo, 2016, 68, 83-89.	0.4	6
31	Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy. PLoS ONE, 2016, 11, e0146622.	1.1	27
32	Identification of a Specific miRNA Profile in HIV-Exposed Seronegative Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 11-19.	0.9	21
33	Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication. Scientific Reports, 2016, 6, 27148.	1.6	49
34	Cell-Mediated Immunity in HIV-Infected Males With Human Papillomavirus–Related Anal Dysplastic Lesions. Clinical Infectious Diseases, 2016, 63, 1396-1398.	2.9	1
35	Pseudo-Mannosylated DC-SIGN Ligands as Immunomodulants. Scientific Reports, 2016, 6, 35373.	1.6	36
36	Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients. Scientific Reports, 2016, 6, 28853.	1.6	24

#	Article	IF	CITATIONS
37	Multiple inflammasome complexes are activated in autistic spectrum disorders. Brain, Behavior, and Immunity, 2016, 57, 125-133.	2.0	67
38	Upregulation of inflammasome activity and increased gut permeability are associated with obesity in children and adolescents. International Journal of Obesity, 2016, 40, 1026-1033.	1.6	60
39	Short Communication: Immune Activation Is Present in HIV-1-Exposed Seronegative Individuals and Is Independent of Microbial Translocation. AIDS Research and Human Retroviruses, 2016, 32, 129-133.	0.5	39
40	Immunomodulatory activity of pidotimod administered with standard antibiotic therapy in children hospitalized for community-acquired pneumonia. Journal of Translational Medicine, 2015, 13, 288.	1.8	30
41	Variants in the CYP7B1 gene region do not affect natural resistance to HIV-1 infection. Retrovirology, 2015, 12, 80.	0.9	1
42	Prospective Immune Dynamics during the First 24 Weeks of Efavirenz Based-Antiretroviral Therapy in HIV-1-Infected Subjects, According to CD4+ T-Cell Counts at Presentation: The IMMUNEF Clinical Trial. PLoS ONE, 2015, 10, e0117118.	1.1	6
43	Designing nanomolar antagonists of DC-SIGN-mediated HIV infection: ligand presentation using molecular rods. Chemical Communications, 2015, 51, 3816-3819.	2.2	74
44	Human papilloma virus vaccination induces strong human papilloma virus specific cell-mediated immune responses in HIV-infected adolescents and young adults. Aids, 2015, 29, 739-743.	1.0	9
45	Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response. Journal of Clinical Immunology, 2015, 35, 550-557.	2.0	42
46	A Regulatory Polymorphism in HAVCR2 Modulates Susceptibility to HIV-1 Infection. PLoS ONE, 2014, 9, e106442.	1.1	13
47	A role for Waldeyer's ring in immunological response to allergens. Current Medical Research and Opinion, 2014, 30, 203-205.	0.9	26
48	Pseudo-Mannosylated DC-SIGN Ligands as Potential Adjuvants for HIV Vaccines. Viruses, 2014, 6, 391-403.	1.5	25
49	Evolutionary Analysis Identifies an MX2 Haplotype Associated with Natural Resistance to HIV-1 Infection. Molecular Biology and Evolution, 2014, 31, 2402-2414.	3.5	28
50	Plasma and PBMC miRNA Profile in Sexually HIV-1 Exposed Seronegative Individuals. AIDS Research and Human Retroviruses, 2014, 30, A83-A83.	0.5	0
51	Evolutionary Analysis Identifies an MX2 Haplotype Associated with Natural Resistance to HIV-1 Infection. AIDS Research and Human Retroviruses, 2014, 30, A24-A25.	0.5	Ο
52	Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine, 2014, 32, 5657-5661.	1.7	54
53	No cure of HIV infection in a child despite early treatment and apparent viral clearance. Lancet, The, 2014, 384, 1320.	6.3	52
54	One night on-call: Sleep deprivation affects cardiac autonomic control and inflammation in physicians. European Journal of Internal Medicine, 2013, 24, 664-670.	1.0	94

#	Article	IF	CITATIONS
55	Endoplasmic reticulum aminopeptidase 2 haplotypes play a role in modulating susceptibility to HIV infection. Aids, 2013, 27, 1697-1706.	1.0	28
56	Cholecalciferol Supplementation in HIV-Infected Youth with Vitamin D Insufficiency: Effects on Vitamin D Status and T-Cell Phenotype: A Randomized Controlled Trial. HIV Clinical Trials, 2013, 14, 51-60.	2.0	47
57	Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. Aids, 2013, 27, 381-389.	1.0	46
58	Immunomodulating activity of Pidotimod in children with Down syndrome. Journal of Biological Regulators and Homeostatic Agents, 2013, 27, 253-8.	0.7	13
59	Neurocognitive Impairment in HIV-Infected NaÃ ⁻ ve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation. Clinical and Developmental Immunology, 2012, 2012, 1-5.	3.3	43
60	The PD-1/PD-L1 Pathway in Human Pathology. Current Molecular Medicine, 2012, 12, 259-267.	0.6	58
61	Mucosal immunoglobulin A in HIV-exposed seronegative individuals. Aids, 2012, 26, 2247-2250.	1.0	2
62	Probiotics Reduce Gut Microbial Translocation and Improve Adult Atopic Dermatitis. Journal of Clinical Gastroenterology, 2012, 46, S33-S40.	1.1	104
63	A glycomimetic compound inhibits DC-SIGN-mediated HIV infection in cellular and cervical explant models. Aids, 2012, 26, 127-137.	1.0	58
64	In Vivo Imaging of Lymph Node Migration of MNP- and 1111n-Labeled Dendritic Cells in a Transgenic Mouse Model of Breast Cancer (MMTV-Ras). Molecular Imaging and Biology, 2012, 14, 183-196.	1.3	19
65	Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA―pilot randomized trial. Mucosal Immunology, 2011, 4, 554-563.	2.7	177
66	Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease. Digestive and Liver Disease, 2011, 43, 946-952.	0.4	53
67	CCL28 Induces Mucosal Homing of HIV-1-Specific IgA-Secreting Plasma Cells in Mice Immunized with HIV-1 Virus-Like Particles. PLoS ONE, 2011, 6, e26979.	1.1	28
68	Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy–treated immunologic nonresponders. Blood, 2011, 118, 3263-3272.	0.6	158
69	In vivo imaging of immune cell trafficking in cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 949-968.	3.3	63
70	Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy. Aids, 2010, 24, 1991-2000.	1.0	116
71	Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART. Aids, 2010, 24, 1455-1460.	1.0	33
72	TLR Activation Pathways in HIV-1–Exposed Seronegative Individuals. Journal of Immunology, 2010, 184, 2710-2717.	0.4	76

#	Article	IF	CITATIONS
73	Immunological Effects of Sublingual Immunotherapy: Clinical Efficacy Is Associated with Modulation of Programmed Cell Death Ligand 1, IL-10, and IgG4. Journal of Immunology, 2010, 185, 7723-7730.	0.4	53
74	The MCP-1 Gene (SCYA2) and Mood Disorders: Preliminary Results of a Case-Control Association Study. NeuroImmunoModulation, 2010, 17, 126-131.	0.9	35
75	A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6–35 months. Vaccine, 2010, 28, 6137-6144.	1.7	21
76	CD4+ T Cell Depletion, Immune Activation and Increased Production of Regulatory T Cells in the Thymus of HIV-Infected Individuals. PLoS ONE, 2010, 5, e10788.	1.1	51
77	Qualitative Immune Modulation by Interleukin-2 (IL-2) Adjuvant Therapy in Immunological Non Responder HIV-Infected Patients. PLoS ONE, 2010, 5, e14119.	1.1	16
78	Costimulatory Pathways in Multiple Sclerosis: Distinctive Expression of PD-1 and PD-L1 in Patients with Different Patterns of Disease. Journal of Immunology, 2009, 183, 4984-4993.	0.4	83
79	HLA and Autoimmune Digestive Disease: A Clinically Oriented Review for Gastroenterologists. American Journal of Gastroenterology, 2009, 104, 195-217.	0.2	48
80	T Lymphocyte Maturation Is Impaired in Healthy Young Individuals Carrying Trisomy 21 (Down) Tj ETQq0 0 0 rgB1	/Qverloci	2 10 Tf 50 46
81	Treatment of periodontal disease results in improvements in endothelial dysfunction and reduction of the carotid intimaâ€media thickness. FASEB Journal, 2009, 23, 1196-1204.	0.2	127
82	Immunomodulatory Effects of 1,25-Dihydroxyvitamin D3 on TH1/TH2 Cytokines in Inflammatory Bowel Disease: An <i>in Vitro</i> Study. International Journal of Immunopathology and Pharmacology, 2009, 22, 63-71.	1.0	74

83	Cytokine Polymorphisms in the Pathophysiology of Mood Disorders. CNS Spectrums, 2009, 14, 419-425.	0.7	80
84	The â€~immunologic advantage' of HIV-exposed seronegative individuals. Aids, 2009, 23, 161-175.	1.0	106
85	Interferon-Î ³ and Granulocyte-Macrophage Colony Stimulating Factor Therapy in Three Patients with Pulmonary Aspergillosis. Infection, 2008, 36, 368-373.	2.3	39
86	CD4+CD25+FoxP3+PD1— regulatory T cells in acute and stable relapsingâ€remitting multiple sclerosis and their modulation by therapy. FASEB Journal, 2008, 22, 3500-3508.	0.2	62
87	Fully Immunocompetent CD8+ T Lymphocytes Are Present in Autologous Haematopoietic Stem Cell Transplantation Recipients Despite an Ineffectual T-Helper Response. PLoS ONE, 2008, 3, e3616.	1.1	4
88	Immune activation and normal levels of endogenous antivirals are seen in healthy adolescents born of HIV-infected mothers. Aids, 2007, 21, 245-248.	1.0	16
89	Protease Inhibitor–Associated Increased Risk of Preterm Delivery Is an Immunological Complication of Therapy. Journal of Infectious Diseases, 2007, 195, 914-916.	1.9	28

90Apolipoprotein B mRNA–Editing Enzyme, Catalytic Polypeptide–Like 3G: A Possible Role in the Resistance
to HIV of HIVâ€Exposed Seronegative Individuals. Journal of Infectious Diseases, 2007, 195, 960-964.1.987

DARIA LUCIA TRABATTONI

#	Article	IF	CITATIONS
91	Effects of Specific Immunotherapy on the B7 Family of Costimulatory Molecules in Allergic Inflammation. Journal of Immunology, 2007, 178, 1931-1937.	0.4	16
92	IL-22 Participates in an Innate Anti-HIV-1 Host-Resistance Network through Acute-Phase Protein Induction. Journal of Immunology, 2007, 178, 407-415.	0.4	83
93	PIN1 promoter polymorphisms are associated with Alzheimer's disease. Neurobiology of Aging, 2007, 28, 69-74.	1.5	86
94	The Mucosae-Associated Epithelial Chemokine (MEC/CCL28) Modulates Immunity in HIV Infection. PLoS ONE, 2007, 2, e969.	1.1	26
95	Antiretroviral compounds affect the granule-dependent mechanisms of lysis in CD8 T cells. Retrovirology, 2006, 3, 1.	0.9	0
96	Failure to eradicate HIV despite fully successful HAART initiated in the first days of life. Journal of Pediatrics, 2006, 148, 389-391.	0.9	26
97	Hiv-specific secretory IgA in breast milk of HIV-positive mothers is not associated with protection against HIV transmission among breast-fed infants. Journal of Pediatrics, 2006, 149, 611-616.	0.9	52
98	Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice. Vaccine, 2006, 24, 1470-1477.	1.7	6
99	Synergy between mannose-binding lectin gene polymorphisms and supplementation with vitamin A influences susceptibility to HIV infection in infants born to HIV-positive mothers. American Journal of Clinical Nutrition, 2006, 84, 610-615.	2.2	19
100	Unusual presentation of acute cytomegalovirus disease during primary HIV-1 infection: antigen-specific T-cell response analyses and clinical outcome. Aids, 2006, 20, 1566-1567.	1.0	4
101	Low interleukin-10 production is associated with diabetes in HIV-infected patients undergoing antiviral therapy. Medical Microbiology and Immunology, 2006, 195, 125-132.	2.6	7
102	Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. Journal of Reproductive Immunology, 2006, 70, 143-150.	0.8	85
103	Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. Journal of Medical Virology, 2006, 78, 440-445.	2.5	40
104	An Immunological Comparison of Third Companion in Advanced Drug-Naive HIV-Infected Patients. HIV Clinical Trials, 2006, 7, 221-228.	2.0	4
105	Distinct patterns of HIV-specific memory T lymphocytes in HIV-exposed uninfected individuals and in HIV-infected patients. Aids, 2005, 19, 653-661.	1.0	34
106	Genotypes at chromosome 22q12-13 are associated with HIV-1-exposed but uninfected status in Italians. Aids, 2005, 19, 1015-1024.	1.0	32
107	Programmed cell death of myelin basic protein-specific T lymphocytes is reduced in patients with acute multiple sclerosis. Journal of Neuroimmunology, 2005, 166, 173-179.	1.1	21
108	Alpha-defensins in the prevention of HIV transmission among breastfed infants. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 138-42.	0.9	43

DARIA LUCIA TRABATTONI

#	Article	IF	CITATIONS
109	Human α Defensin in HIV-Exposed But Uninfected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 455-463.	0.9	73
110	Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiology of Aging, 2004, 25, 1009-1015.	1.5	131
111	Growth hormone in T-lymphocyte thymic and postthymic development: A study in HIV-infected children. Journal of Pediatrics, 2004, 145, 542-548.	0.9	32
112	Granule-dependent mechanisms of lysis are defective in CD8 T cells of HIV-infected, antiretroviral therapy-treated individuals. Aids, 2004, 18, 859-869.	1.0	36
113	Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial. Antiviral Therapy, 2004, 9, 603-14.	0.6	3
114	Immunomodulation Induced by Tucaresol in HIV Infection: Results of a 16 Week Pilot Phase I/II Trial. Antiviral Therapy, 2004, 9, 603-614.	0.6	13
115	Distinct immune profiles characterize patients with diffuse or limited systemic sclerosis. Clinical Immunology, 2003, 108, 21-28.	1.4	27
116	Productive Infection Maintains a Dynamic Steady State of Residual Viremia in Human Immunodeficiency Virus Type 1-Infected Persons Treated with Suppressive Antiretroviral Therapy for Five Years. Journal of Virology, 2003, 77, 11212-11219.	1.5	136
117	Assessment of immune reconstitution to Pneumocystis carinii in HIV-1 patients under different highly active antiretroviral therapy regimens. Journal of Antimicrobial Chemotherapy, 2003, 52, 276-281.	1.3	17
118	Research on Psychoimmunology. World Journal of Biological Psychiatry, 2003, 4, 119-123.	1.3	9
119	Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. Aids, 2003, 17, 531-539.	1.0	80
120	IL-4 and CXCR4 upregulation in HIV-infected and uninfected individuals from Maharashtra-Mumbai. Aids, 2003, 17, 1563-1565.	1.0	10
121	Cytokine production in women with antiretroviral treatment-associated breast fat accumulation and limb wasting. Aids, 2003, 17, S155-S161.	1.0	6
122	B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood, 2003, 101, 2514-2520.	0.6	157
123	Detection of Mucosal Antibodies in HIV Type 1-Infected Individuals. AIDS Research and Human Retroviruses, 2002, 18, 1291-1300.	0.5	72
124	Immune Profiles of Patients with Chronic Idiopathic Urticaria. International Archives of Allergy and Immunology, 2002, 128, 59-66.	0.9	86
125	Modulation of Human Immunodeficiency Virus (HIV)-Specific Immune Response by Using Efavirenz, Nelfinavir, and Stavudine in a Rescue Therapy Regimen for HIV-Infected, Drug-Experienced Patients. Vaccine Journal, 2002, 9, 1114-1118.	3.2	9
126	Selective granulocyte/monocyte apheresis in the treatment of HIV-infected patients: short-term and long-term effects on immunological and virological parameters. Perfusion (United Kingdom), 2002, 17, 47-51.	0.5	18

#	Article	IF	CITATIONS
127	Lowâ€Dose Prolonged Intermittent Interleukinâ€2 Adjuvant Therapy: Results of a Randomized Trial among Human Immunodeficiency Virus–Positive Patients with Advanced Immune Impairment. Journal of Infectious Diseases, 2002, 186, 606-616.	1.9	63
128	Cross-Clade HIV-1–Specific Neutralizing IgA in Mucosal and Systemic Compartments of HIV-1–Exposed, Persistently Seronegative Subjects. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 30, 413-420.	0.9	118
129	Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients. Aids, 2002, 16, 1767-1773.	1.0	16
130	Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the α-helix of gp41. Aids, 2002, 16, 1731-1741.	1.0	75
131	Thymic volume predicts long-term immune reconstitution in HIV-infected children treated with highly active antiretroviral therapy. Aids, 2002, 16, 2219-2221.	1.0	22
132	Cytokine profiles in schizophrenic patients treated with risperidone. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 33-39.	2.5	86
133	Granulocyte/monocyte apheresis induces sustained increases in CD4 T cells in HIV-1 infected patients with poor CD4 T cell restoration after suppression of viral replication by HAART. Journal of Biological Regulators and Homeostatic Agents, 2002, 16, 58-63.	0.7	2
134	Evaluation of Immune Activation in HIV-Infected and Uninfected African Individuals by Single-Cell Analysis of Cytokine Production. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 429-436.	0.9	14
135	Reduced HIV-stimulated T-helper cell reactivity in cord blood with short-course antiretroviral treatment for prevention of maternal-infant transmission. Clinical and Experimental Immunology, 2001, 123, 443-450.	1.1	17
136	PCP Occurring in HIV Patients Under HAART: Assessment of Specific Immunity Against P. carinii. Journal of Eukaryotic Microbiology, 2001, 48, 152s-152s.	0.8	1
137	Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease. Journal of Neuroimmunology, 2001, 121, 88-101.	1.1	54
138	T-helper cell responses to HIV envelope peptides in cord blood: protection against intrapartum and breast-feeding transmission. Aids, 2001, 15, 1-9.	1.0	93
139	Interferon-Gamma and Interleukin-10 Production Among HIV-1–Infected and Uninfected Infants of HIV-1–Infected Mothers. Pediatric Research, 2001, 50, 412-416.	1.1	31
140	Evaluation of Immune Activation in HIV-Infected and Uninfected African Individuals by Single-Cell Analysis of Cytokine Production. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 429-436.	0.9	0
141	Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naÃ ⁻ ve patients with undetectable viraemia. Aids, 2000, 14, 109-116.	1.0	38
142	Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. Aids, 2000, 14, 2083-2092.	1.0	112
143	Study of immunological and virological parameters during thalidomide treatment of SIV-infected cynomolgus monkeys. Journal of Medical Primatology, 2000, 29, 1-10.	0.3	4
144	Effect of two different combinations of antiretrovirals (AZT+ddl and AZT+3TC) on cytokine production and apoptosis in asymptomatic HIV infection. Antiviral Research, 2000, 46, 171-179.	1.9	11

#	Article	IF	CITATIONS
145	Post-kala-azar Dermal Leishmaniasis During Highly Active Antiretroviral Therapy in an AIDS Patient Infected withLeishmania infantum. Journal of Infection, 2000, 40, 199-202.	1.7	63
146	Tumor Necrosis Factor–α Increased Production during Thalidomide Treatment in Patients with Tuberculosis and Human Immunodeficiency Virus Coinfection. Journal of Infectious Diseases, 2000, 182, 639-639.	1.9	13
147	Transient Detection of Plasma HIV-1 RNA During Postexposure Prophylaxis. Infection Control and Hospital Epidemiology, 2000, 21, 529-531.	1.0	8
148	Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease. Aids, 2000, 14, 1859-1861.	1.0	10
149	Human Immunodeficiency Virus (HIV)–Specific IgA and HIV Neutralizing Activity in the Serum of Exposed Seronegative Partners of HIV‧eropositive Persons. Journal of Infectious Diseases, 1999, 180, 871-875.	1.9	135
150	Aminooxypentane-RANTES, an Inhibitor of R5 Human Immunodeficiency Virus Type 1, Increases the Interferon gamma to Interleukin 10 Ratio without Impairing Cellular Proliferation. AIDS Research and Human Retroviruses, 1999, 15, 861-867.	0.5	7
151	Intractable pruritus in HIV infection: immunologic characterization. Allergy: European Journal of Allergy and Clinical Immunology, 1999, 54, 266-272.	2.7	30
152	A role for mucosal immunity in resistance to HIV infection. Immunology Letters, 1999, 66, 21-25.	1.1	16
153	The Effects of CD40 Ligation on Peripheral Blood Mononuclear Cell Interleukin-12 and Interleukin-15 Production and on Monocyte CD14 Surface Antigen Expression in Human Immunodeficiency Virus-Positive Patients. Scandinavian Journal of Immunology, 1999, 49, 286-292.	1.3	6
154	lmmune responses to antigens of human endogenous retroviruses in patients with acute or stable multiple sclerosis. Journal of Neuroimmunology, 1999, 99, 173-182.	1.1	32
155	Vaccine strategies for infectious diseases. Expert Opinion on Investigational Drugs, 1999, 8, 95-106.	1.9	6
156	Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection. Journal of Pediatrics, 1999, 135, 675-682.	0.9	33
157	HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. Aids, 1999, 13, 23-29.	1.0	235
158	Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1998, 22, 947-957.	2.5	99
159	Immunization with Both T Cell-Dependent and T Cell-Independent Vaccines Augments HIV Viral Load Secondarily to Stimulation of Tumor Necrosis Factor α. AIDS Research and Human Retroviruses, 1998, 14, 727-734.	0.5	43
160	Immune activation in HIV-infected African individuals. Aids, 1998, 12, 2387-2396.	1.0	77
161	Pentoxyfylline Improves Cell-Mediated Immunity and Reduces Human Immunodeficiency Virus (HIV) Plasma Viremia in Asymptomatic HIV-Seropositive Persons. Journal of Infectious Diseases, 1997, 175, 1210-1215.	1.9	24
162	Cytokine Production Patterns in Cervical Intraepithelial Neoplasia: Association With Human Papillomavirus Infection. Journal of the National Cancer Institute, 1997, 89, 245-250.	3.0	232

#	Article	IF	CITATIONS
163	Type 1 and Type 2 Cytokines in HIV Infection – A Possible Role in Apoptosis and Disease Progression. Annals of Medicine, 1997, 29, 185-188.	1.5	44
164	Long-Term Resistance to HIV Infection in Vertical HIV Infection: Cytokine Production, HIV Isolation, and HIV Phenotype Define Long-Term Resistant Hosts. Pathobiology, 1997, 65, 169-176.	1.9	13
165	HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nature Medicine, 1997, 3, 1250-1257.	15.2	399
166	A possible role for the cortisol/anticortisols imbalance in the progression of human immunodeficiency virus. Psychoneuroendocrinology, 1997, 22, S27-S31.	1.3	72
167	Chemokine production in HIV-seropositive long-term asymptomatic individuals. Aids, 1996, 10, 1432-1433.	1.0	51
168	Evidence for type 2 cytokine production and lymphocyte activation in the early phases of HIV-1 infection. Aids, 1996, 10, 23-30.	1.0	44
169	Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clinical and Experimental Immunology, 1996, 106, 127-133.	1.1	557
170	Type 1 Cytokine Production and Low Prevalence of Viral Isolation Correlate with Long-Term Nonprogression in HIV Infection. AIDS Research and Human Retroviruses, 1996, 12, 1053-1061.	0.5	94
171	Virologie and Immunologic Markers of Disease Progression in Pediatrie HIV Infection. AIDS Research and Human Retroviruses, 1996, 12, 1255-1262.	0.5	21
172	The breakdown of the cytokine network subsequent to human immunodeficiency virus infection. Mediators of Inflammation, 1995, 4, 315-321.	1.4	2
173	Restorative effect of total parenteral nutrition on natural killer cell activity in malnourished cancer patients. European Journal of Cancer, 1995, 31, 2023-2027.	1.3	11
174	Immunologic characterization of children vertically infected with human immunodeficiency virus, with slow or rapid disease progression. Journal of Pediatrics, 1995, 126, 368-374.	0.9	71
175	Multiple defects of T helper cell function in newly diagnosed patients with Hodgkin's disease. European Journal of Cancer, 1994, 30, 1464-1470.	1.3	33
176	Retinoids, breast cancer and NK cells. British Journal of Cancer, 1993, 68, 845-850.	2.9	21